We are live on ! Find out more
CALA

Calithera Biosciences, Inc
CALA

Delisted

CALA was delisted on the 1st of February, 2023.

Back to rankings

54 hedge funds and large institutions have $17.9M invested in Calithera Biosciences, Inc in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,533% more call options, than puts

Call options by funds: $139K | Put options by funds: $3K

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

2% less funds holding

Funds holding: 55 → 54 (-1)

34% less capital invested

Capital invested by funds: $27M → $17.9M (-$9.1M)

Holders
54
Holders Change
-1
Holders Change %
-1.82%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
12
Reduced
12
Closed
14
Calls
$139K
Puts
$3K
Net Calls
+$136K
Net Calls Change
-$45K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$941K
2
AAA
Affinity Asset Advisors
New York
+$511K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$511K
4
EAM
Empery Asset Management
New York
+$396K
5
Renaissance Technologies
Renaissance Technologies
New York
+$253K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$653K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$480K
3
AFM
Anson Funds Management
Texas
-$427K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$370K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$317K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
$1K – – –
SCM
52
Silverarc Capital Management
Massachusetts
$74 +$1.02K +100 +0.9%
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$49 -$920 -90 -94%
Jacobs Levy Equity Management
54
Jacobs Levy Equity Management
New Jersey
– -$480K -36,063 Closed
AFM
55
Anson Funds Management
Texas
– -$427K -32,063 Closed
Dimensional Fund Advisors
56
Dimensional Fund Advisors
Texas
– -$317K -23,814 Closed
Jane Street
57
Jane Street
New York
– -$67K -5,001 Closed
CM
58
Caption Management
Oklahoma
– -$55K -4,081 Closed
Susquehanna International Group
59
Susquehanna International Group
Pennsylvania
– -$24K -2,348 Closed
Charles Schwab
60
Charles Schwab
California
– -$31K -2,318 Closed
EGM
61
Engineers Gate Manager
New York
– -$16K -1,171 Closed
E
62
Ergoteles
New York
– -$13K -965 Closed
TSS
63
Two Sigma Securities
New York
– -$13K -941 Closed
AG
64
Algert Global
California
– -$11K -840 Closed
TRCT
65
Tower Research Capital (TRC)
New York
– -$6K -440 Closed
ACM
66
Aquatic Capital Management
Illinois
– -$3K -235 Closed
TC
67
Truvestments Capital
Florida
– -$1K -65 Closed
PFS
68
Prospera Financial Services
Texas
– +$255 +25 New
1 2
3

CALA Hedge Fund Activity: Q1 2022 in Review

54 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q1 2022, worth a combined $17.9M — down 34% from $27M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CALA and 13 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 12 added.

The largest buyer was BVF Inc, adding an estimated $941K. The largest seller was D.E. Shaw & Co, cutting an estimated $653K.

  • 54 institutional investors held Calithera Biosciences, Inc (CALA) as of Q1 2022, down from 55 in Q4 2021.
  • Funds reported $17.9M of Calithera Biosciences, Inc stock for Q1 2022, down 34% quarter-over-quarter.
  • 13 funds opened new Calithera Biosciences, Inc positions in Q1 2022 and 14 closed out, a net change of -1 holder.
  • The largest Calithera Biosciences, Inc buyer in Q1 2022 was BVF Inc, an estimated $941K added.
  • The largest Calithera Biosciences, Inc seller in Q1 2022 was D.E. Shaw & Co, an estimated $653K sold.

Based on aggregated 13F filings for Q1 2022.